[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
RE: Merck published fake journal
- To: <liblicense-l@lists.yale.edu>
- Subject: RE: Merck published fake journal
- From: "Ian Russell" <ian.russell@cytherean.co.uk>
- Date: Fri, 15 May 2009 02:18:36 EDT
- Reply-to: liblicense-l@lists.yale.edu
- Sender: owner-liblicense-l@lists.yale.edu
I won't comment on the details of what has happened in the Merck /Elsevier case. It does seem that a line was crossed, which is unfortunate to say the least, but that some of the subsequent comments I've read are over the top... However, the point I'd like to make is about quality and business models. It is a fact that subscription journals vary widely in quality. I am sure that the same will be true for open access journals. I really can't see much of a difference. A subscription journal might be tempted to accept lower quality material if it is struggling to fill its pages just as an author-pays journal may be tempted to accept a paper to generate income. The result in both cases is the same; a lower quality publication. Impact factors etc give an indication of 'quality' but as Anthony says below the academics know the quality of the journals they interact with. What often seems to be ignored is that the journals market is fiercely competitive - the competition is for good papers from good authors who will improve the standard of the journal and that is why wise journals will resist the temptation to accept low quality work irrespective of their business model. It is of course true that subscribers are more likely to purchase higher quality journals and this provides a strong incentive for journals to strive to improve their quality. Perhaps one of the open access publishers could provide a similar motivation for improving the quality of their journals? Ian Russell, ALPSP -----Original Message----- From: owner-liblicense-l@lists.yale.edu [mailto:owner-liblicense-l@lists.yale.edu] On Behalf Of anthony.watkinson@btinternet.com Sent: 14 May 2009 02:43 To: liblicense-l@lists.yale.edu Subject: RE: Merck published fake journal David and all: Alas there are temptations involved in all business models. It was my understanding that Elsevier immediately condemned the "fake journal" published some time ago. Anyone who works in publishing or who has once worked in publishing must be aware of the pressures that will have led to this improper publication and also that such a publication can be done without proper management approval - which is what Elsevier claim. My complaint about irony was the suggestion that that such practices may be common in Elsevier. There must be a temptation to those who publish large numbers of new OA author paid journals with very few submissions to (let us say) lower standards. I have not checked out these journals and do not know whether this is in fact going on, but if I was running a company which was going down the tubes I would be tempted. I am not making covert attacks on BMC, or PLOS or Hindawi or publishers like that, and I certainly will not provide any names, but the academic communities know them. Anthony Watkinson
- Prev by Date: Re: Merck published fake journal
- Next by Date: RE: Merck published fake journal
- Previous by thread: Re: Merck published fake journal
- Next by thread: RE: Merck published fake journal
- Index(es):